Background. Since the emergence of influenza A(H7N9) virus in 2013, there have been 5 waves of influenza A(H7N9) epidemics in China. However, evolution of the hemagglutinin (HA) protein antigenicity has not been systematically investigated.
Since the first report of influenza A(H7N9) virus infections in humans, 5 epidemic waves have been observed, which had public health authorities around the world on high alert for the potential development of a human influenza pandemic [1] [2] [3] [4] . It is important to determine the evolution pattern of the hemagglutinin (HA) protein of this virus because it is the major viral glycoprotein mediating the adsorption and penetration of virus into the host cell [5] [6] [7] [8] . HA protein facilitates virus entry by binding sialic acid receptor on the host membrane through its receptor binding site (RBS), including the 190 helix and the 130, 150, and 220 loops [9] [10] [11] [12] [13] [14] . Antibodies against HA protein can neutralize the virus by directly blocking the initial attachment of the virus to the target cells [12, 15, 16] . It is well established that HA protein is the antigenic target of vaccine-induced neutralizing antibodies. As a result, HA protein is considered the most important component in current influenza vaccines. Clearly, mutations in the gene encoding HA protein could drastically alter the antigenicity of the virus, thereby rendering the vaccines less effective [17] [18] [19] . Previous studies have identified 5 immune-dominant antigenic sites (AS; referred to as A to E) in HA protein derived from H1 and H3 [8, [19] [20] [21] [22] . Given the similar 3-dimensional structures in HA protein of all viruses analyzed so far, it would be of great interest to investigate the evolutionary pattern of the 5 antigenic sites in HA protein derived from influenza A(H7N9) viruses [23, 24] . In this study, we found some critical mutations that resulted in drastic changes in their reactions to neutralizing antibodies; moreover, we demonstrated better protection against the dominant virus strains through DNA vaccination targeting these newly-emerged virus.
MATERIALS AND METHODS

Determination of Naturally Occurring Single Amino Acid Substitutions of Influenza A(H7N9) Virus HA Protein
The HA protein sequence derived from influenza A/ Anhui/1/2013(H7N9) virus (hereafter, "A/Anhui") was selected as a reference in this study. All previously published HA protein sequences of influenza A(H7N9) viruses isolated from human as of 30 September 2017 were downloaded from the National Center for Biotechnology Information and Global Initiative on Sharing All Influenza Data (GISAID) databases. All sequences were separately aligned with the reference by using Bioedit software in conjunction with manual editing. We removed duplicate sequences from this data set, generating 902 influenza A(H7N9) virus HA protein sequences.
Cells
293FT cells were cultured in growth medium (complete Dulbecco's modified Eagle's medium (DMEM) with 10% fetal bovine serum (FBS), 2% HEPES, 1% nonessential amino acids and 1% penicillin/streptomycin) and maintained in DMEM with 1% FBS, 2% HEPES, 1% nonessential amino acids and 1% penicillin/streptomycin. Madin-Darby canine kidney (MDCK) cells were grown in DMEM supplemented with 10% FBS, 2% HEPES, and 1% penicillin/streptomycin. All cells were grown at 37°C in a humidified 5% CO 2 incubator.
Plasmid Construction and Site-Directed Mutagenesis
The coding sequences of HA gene (GenBank accession no. KC853228) and neuraminidase gene (NA; GenBank accession no. KC853231) derived from A/Anhui were synthesized and separately cloned into the eukaryotic expression vector pSV1.0, generating 2 recombinant plasmids pSV1.0-A/Anhui HA and pSV1.0-A/Anhui NA. PSV1.0-A/Anhui HA was used as template to make the HA protein variants. Mutations were introduced according to amino acid sequences observed in naturally occurring mutants with various amino acid substitutions. All variants were obtained by site-directed mutation with specific polymerase chain reaction primers (Supplementary Table 1) .
Generation of Influenza A(H7N9) Mutant HANA Pseudoviruses
Plasmids containing wild-type or the mutated HA genes were used to generate HIV-based influenza A(H7N9) pseudovirus (p/HIV/HA/NA/Fluc). Briefly, 293FT cells were cultured in growth medium to form a monolayer and then were cotransfected with 15 μg of lentivirus vector SG3-M2-Fluc R-E-, 7.5 μg of pSV1.0-A/Anhui HA, and 7.5 μg of pSV1.0-A/Anhui NA by using Lipofectamine 2000 (Thermo Scientific, Waltham, MA). Subsequently, transfection medium was replaced by maintenance medium. After overnight incubation, 1 mL of maintenance medium and 500 μL 1 mol/L NaHCO3 were added to the cells. The pseudovirus-containing supernatant was harvested at 48 hours and centrifuged at 1800g for 5 minutes. Afterward, trypsin enzyme was added to the supernatant in a 1:9 ratio, and the supernatant plus enzyme were incubated for 30 minutes at room temperature. Finally, the reaction was stopped by addition of trypsin inhibitor (Zuomanbio, Beijing, China) in a 1:33 ratio.
MDCK cells were infected with serially diluted pseudovirus stock, and the infectivity based on the relative luciferase activity (RLA) was defined as 50% tissue culture infective dose (TCID 50 ), according to the method of Reed and Muench.
Sera From Guinea Pigs Immunized With Influenza A(H7N9) Virus HA DNA
Vaccine
The animal study was approved by the Institutional Animal Care and Use Committee of the Chinese National Institute of Food and Drug Control. All animals were housed in accordance with relevant guidelines. Four groups of guinea pigs (6 per group) were inoculated with one of the following plasmids: pSV1.0-A/Anhui HA (A/Anhui vaccine), pSV1.0-A/Anhui HA-A143V (A/Anhui A143V vaccine), pSV1.0-A/Anhui HA-R148K (A/Anhui R148K vaccine), and pSV1.0-A/Anhui HA-A143V/R148K (A/Anhui A143V/R148K vaccine). Two hundred-microgram plasmids were delivered by electroporation into guinea pigs (weight, 200-220 g; sex, female). Immunization was repeated twice at 2-week intervals, while sera were obtained 2 weeks after the second immunization. All serum samples were inactivated before the first use.
Pseudotype-Based Neutralization Assay
Neutralization of the infectious pseudoviruses was assessed as described elsewhere [25] . Briefly, MDCK cells were seeded at 1.0 × 10 4 cells/100 μL/well and incubated overnight. Pseudoviruses were mixed with antibodies for 1 hour at 37°C and added to the MDCK cultures, after which cultures were incubated for 48 hours. Afterward, RLA was measured according to the instruction manual provided by PerkinElmer (Waltham, MA). Inhibition percentage was calculated as the following: [(RLA in virus challenge control) − (RLA in test samples)]/RLA in virus challenge control. Serum neutralization titers were defined as 50% maximal inhibitory dilutions (ID 50 ) and calculated with the Reed-Muench method.
RESULTS
Identification of Substitution Mutants
We analyzed 902 influenza A(H7N9) virus HA protein sequences and found 303 mutations, with frequencies ranging from 0.11% to 39.58%.We next chose 16 single amino acid mutations that had frequencies of >5%. These 16 substitutions were called hot substitutions, and their mutation frequencies are shown in Supplementary Table 2. We also identified 20 variants, which were located in the putative antigenic binding sites; these 20 variants were found at 13 locations. We denoted them as AS-related substitutions (Supplementary Table 2 ). Furthermore, 40 variants involving 23 positions inside the RBS (ie, the 130, 150, and 220 loops and 190 helices) were also chosen for our study. We designated these variants as RBS-related substitutions (Supplementary Table 2 ). All 53 mutants were introduced into pseudoviruses, with their GISAID accession numbers listed in Supplementary Table 1 .
Temporal Circulation of Substitution Mutants Over the 5 Epidemic Waves
After we identified variants that could potentially affect antigenicity, we investigated their respective temporal circulation pattern. As shown in Supplementary Table 3, 19 variants demonstrated certain circulating patterns, with frequencies in an upward or downward trend, over the 5 epidemic waves. Circulation of 9 substitutions-A130T, S136N, A143V, R148K, L186I, A169T, E396A, V439I, and S499R-was found to be increasing. Of note, a trend for decreasing circulation was found in the remaining 10 variants: E122K, N141S, N141D, A143T, R148G, G151E, Q231P, G234D, L235S, and K414T. Moreover, among the other 34 variants, 20 were found to be wave-specific substitutions (ie, substitutions only existing in 1 epidemic wave), whereas the remaining 14 substitutions, whose frequency fluctuated irregularly over the 5 epidemic waves, had no clear trend with respect to temporal circulation.
Generation and Infectivity Analysis of Pseudoviruses With Individual Amino Acid Substitution
To generate pseudovirus constructs of the 53 substitutions, we used site-directed mutagenesis to generate mutations on the pSV1.0-A/Anhui HA plasmid. All 53 mutants could form infectious pseudoviruses. Of those, 49 variants had similar or higher infectivity as compared to the reference pseudoviruses (generated from the original pSV1.0-HA plasmid). The other 4 mutant pseudoviruses (D166A, D166N, L235P, and G237E) were >2 orders of magnitude less infectious than the reference pseudoviruses and were not analyzed further (Supplementary Figure 1) .
Analysis of Antigenic Properties, Using Guinea Pig Sera Immunized With pSV1.0-A/Anhui HA
Sera from guinea pigs, collected following two doses of pSV1.0-A/Anhui HA vaccination, were used to assess influenza A(H7N9) virus HA protein variant sensitivity to vaccine-elicited antibodies. Pseudoviruses based on the reference HA protein sequence and all modified sequences displayed quite similar neutralization sensitivities. In other words, none of the tested mutants was sufficient to escape recognition by the sera. However, three variant pseudoviruses were less susceptible to neutralization by all the vaccinated sera than the reference pseudoviruses including A143V, A143T, and R148K, which exhibited a median 4-fold lower titer, indicating altered antigenicity for the A/Anhui strain ( Figure 1 ). All 3 substitutions were within the RBS of HA protein, with R148K also within the Table 2 ).
Antigenic Property of the Variant Containing Both A143V and R148K
Substitutions
A most striking observation from the temporal distribution analysis is the propensity of simultaneous (parallel) multiple amino acid substitutions to occur in the same epidemic waves, especially the 9 substitutions with frequencies trending upward over the 5 epidemic waves (Supplementary Table 3) . Of the 9 aforementioned substitutions, A143V and R148K, whose frequencies suddenly increased to 97.46% and 74.11%, respectively, in wave 5, slightly reduced the antigenic response to the vaccinated sera against A/ Anhui (Figure 1 ). Further analysis revealed that R148K mutation did not occur independently but was always accompanied by the A143V mutation. However, the mutation rate of A143V itself was 23.25%, with the rate of the joint presence of mutations A143V and R148K being as high as 74.11%. These findings suggest that A143V/R148K has become the dominant circulating strain (Figure 2A) . Thus, pseudoviruses with the combination of A143V and R148K were generated to determine whether they would result in more resistance to neutralization than single mutations. The TCID 50 of the double mutant is similar to that of the reference and single-mutant pseudoviruses ( Figure 2B ). Antigenic analyses with vaccinated sera indicated that, compared with the single mutations A143V and R148K, each of which reduced the neutralizing titers of vaccinated sera marginally, by approximately 4-fold, the double mutant exhibited a median 10-fold decrease in susceptibility to the sera ( Figure 2C ), indicating that these substitutions had a cumulative antigenic effect.
The DNA Candidate Vaccine With HA Containing 143V/148K Induced a Better Neutralization Response to the Currently Predominant Strains
The impact of A143V, R148K, and A143V/R148K in the HA protein globular region on immunogenicity and induction of Figure 1 . Differences in the 50% maximal inhibitory dilution (ID 50 ) between variant pseudoviruses (PsVs) and the reference PsVs against guinea pig sera. The serum samples were prediluted serially in 6 steps from 1:1000 to 1:7 776 000. Each point represents the ID 50 difference between a mutant and the reference PsVs. Reference PsVs with ID 50 at least 4-fold higher or lower than those of the mutants were considered substantially antigenically different. neutralization activities was evaluated using the pseudovirus-based neutralization assay. Influenza A(H7N9) DNA vaccine pSV1.0-A/Anhui HA bearing HA protein variant residues A143V, R148K, and A143V/R148K were used as vaccine antigens and are referred to hereafter as A/Anhui A143V, A/Anhui R148K, and A/Anhui A143V/R148K DNA candidate vaccines, respectively. The vaccine-elicited antisera were then subsequently evaluated for their neutralization profile. As shown in Figure 3A , sera immunized with each of 4 aforementioned vaccines exhibited neutralization activities similar to those of the reference A/Anhui pseudoviruses. Compared with A/Anhui, the A/Anhui A143V-induced antisera exhibited a median 2-fold increased neutralization activity to A143V pseudoviruses (P < .01, by the Wilcoxon paired signed rank test), while the A/Anhui R148K and A/Anhui A143V/R148K antisera showed similar neutralization activities ( Figure 3B ). Likewise, compared with A/Anhui, the A/Anhui R148K-induced antisera could better neutralize A148K pseudoviruses, with a 4-fold higher median ID 50 (P < .01), while the A/Anhui A143V or A/ Anhui A143V/R148K antisera showed similar neutralization activities ( Figure 3C ). To A143V/R148K pseudoviruses, the A/ Anhui R148K antisera and the A/Anhui A143V/R148K antisera demonstrated a median 3-fold (P < .01) and 5-fold (P < .05) increase in neutralization activities, respectively, as compared to the A/Anhui-induced antisera, whereas the A/Anhui A143V antisera showed similar neutralization activities ( Figure 3D ).
DISCUSSIONS
Since influenza A(H7N9) virus emerged, the outbreak of infection in human has occurred in 5 epidemic waves. We found that the influenza A(H7N9) virus HA protein is mutating at a high rate, with approximately 1.79 × 10 -3 amino acid substitutions per site per year, which is similar to that for influenza A(H3N2) virus HA protein, whose overall rate for replacement substitutions is 10.8 × 10 −3 codons/year [26] . And more specifically, the mutation rates of influenza A(H7N9) virus HA protein were 3.08, 2.96, 5.39, 8.01, and 19.9 × 10 −3 substitution/site/year in waves 1-5, respectively. Notably, the substitution rate in wave 5 was approximately 19.9 × 10 −3 substitutions/site/year and was far beyond the previous waves, largely in agreement with a previous study demonstrating that HA genes had evolved into 2 lineages in the fifth wave, with increased genotypic diversity [27] . All these results indicated that, over the 5 epidemic waves, influenza A(H7N9) viruses had been evolving quite rapidly and the mutation rate of the HA protein had been accelerating.
In this study, we attempted to identify amino acid variations that contributed to antibody escape of influenza A(H7N9) virus. Substitutions introduced into the HA protein of A/ Anhui were selected on the basis of substitutions within the inferred antigenic sites of influenza A(H7N9) virus HA protein or substitutions associated with changes in receptor binding specificity. All 54 influenza A(H7N9) virus HA protein single and double mutants were able to self-assemble efficiently into infectious pseudoviruses (Supplementary Figure 1 and Figure 2A ). However, obvious differences in pseudovirus yields were observed among the 54 infectious mutants, with 4 variant pseudoviruses having a TCID 50 that was >2 orders of magnitude lower than that of the reference pseudoviruses, owing to lower protein expression or reduced protein solubility, which was consistent with the finding from the previous study that variation in virion yield was contributing to the protein yield because of sequence-specific differences [28, 29] . Notably, all 4 mutants had no clear trend in temporal circulation, with 3 of 4 mutants circulating in a given epidemic wave (D166A in wave 3, L235P in wave1, and G237E in wave 5; Supplementary Table 3) .
Our results showed that sera immunized with influenza A(H7N9) vaccines had neutralizing reactivity against all 49 mutants. These results, together with the facts that influenza A(H7N9) vaccines have not received market authorization and that continuous host immune pressure has not yet appeared for influenza A(H7N9) virus, suggest that these influenza A(H7N9) virus variants would likely be protected in vaccinated persons. The relative neutralization titer of a given serum against the reference pseudoviruses is quite similar to its relative titer against other variants, except for 3 substitutions, including A143V, A143T, and R148K, that showed a median titer 4-fold lower than that of the reference pseudoviruses. For practical consideration, the 4-fold differences in neutralization activity may well be within experimental error. However, we cannot exclude the possibility that these substitutions could be prone to escape from the immune response through further mutations. Notably, of the 3 substitutions, 2, including A143V and A143T, were outside the antigenic sites, indicating that amino acids outside the inferred H7 antigenic sites may also play a role as additional antigenic determinants of viruses. Our finding was consistent with that reported by Deem et al [30] , who demonstrated that more amino acid positions outside the previously defined antigenic site of H1 HA protein may be involved in HA protein antigenicity. Moreover, in agreement with a previous study, in which the authors proposed that, because of the immune response, influenza virus evolved by adjusting receptor binding avidity via amino acid substitutions throughout the HA protein, many of which simultaneously altered antigenicity [31] , all 3 substitutions happened to be within the RBS of the HA protein.
Our evaluation using A/Anhui carrying individual or double mutations revealed that A143V/R148K, rather than A143V or R148K, was most critical in influencing HA protein antigenicity, because pseudoviruses containing A143V/R148K demonstrated a median 10-fold reduction in cross-reactivity to the reference. Temporal analysis showed that, compared with A143V (23.25%) and R148K (0%), the frequency of the A143V/R148K mutant had suddenly increased to 74.11% in wave 5, indicating that it is currently the most dominant strain. Furthermore, A143V/R148K altered A/Anhui vaccine immunogenicity and displayed a 5-fold increase in neutralizing protection for the predominant strain, A143V/R148K, after DNA vaccination. These results suggest that some critical mutations, which altered both immunogenicity and antigenicity, such as A143V and R148K, should be covered in vaccine virus selection. This is consistent with a recent recommendation by the World Health Organization, which suggested A/Hong Kong/125/2017 (containing both 143V and 148K) as a new candidate vaccine strain. Notably, R148K also showed a 3-fold increase in neutralizing protection for strain A143V/R148K, indicating that R148K plays a more important role than A143V in vaccine immunogenicity.
In conclusion, the mutation of influenza A(H7N9) virus HA protein is accelerating, especially in the fifth epidemic wave. A143V/R148K, a strain with a double mutation, contributed to the reduced antigenic response to the vaccinated sera against A/ Anhui, with a frequency that suddenly increased to a remarkable 74.11% in wave 5. In general, the 4-fold differences in neutralization activity between the reference A/Anhui strain and the tested variants are within experimental error. However, the 10-fold reduction observed for the A143V/R148K variant is considered to be significant, indicating that the immune response elicited by candidate vaccine A/Anhui may not contribute to protection against these predominant strains. These findings, if substantiated by future studies using sera against other influenza A(H7N9) candidate vaccine strains, may have important implications for the future selection of vaccine strains. In addition, the A143T mutation has been reported to be a molecular marker for mammalian adaptation and virulence in influenza A(H10N8) virus [32] . Therefore, enhanced surveillance of the antigenic change of influenza A(H7N9) virus is still urgently needed, and the combination of A143V and R148K along with A143T should be closely monitored.
Supplementary Data
Supplementary materials are available at The Journal of Infectious Diseases online. Consisting of data provided by the authors to benefit the reader, the posted materials are not copyedited and are the sole responsibility of the authors, so questions or comments should be addressed to the corresponding author. 
